Analogues of amylin, α-glucosidase inhibitors and the digestive system in homeostasis regulation

Česká verzia

Authors: J. Rybka
Authors place of work: Diabetologické centrum Interní kliniky IPVZ, Krajská nemocnice T. Bati, a. s., Zlín, přednosta prim. MUDr. Jiří Latta
Published in the journal: Vnitř Lék 2011; 57(4): 381-387
Category: 12th national Symposium diabetes, "Diabetes and Gastroenterology", Hradec Kralove, 4 to 5 June 2010

Summary

The digestive tract plays an important role in glucose homeostasis. The important fact is that cells of the digestive tract are also the place of production of numerous regulatory peptides. Their use in the treatment of diabetes has been subject to study for many years. The paper examines the synthetic analogue of the human hormone amylin, the secretion of which coincides with the secretion of insulin. The synthetic analogue pramlintide is used in treatment of DM1Tas well as DM2T. Likewise, a group of intestinal α-glukosidase inhibitors – acarbose in this country – was introduced into clinical practice some years ago. Both drugs share their glucose-lowering effects, but first of all they influence postprandial hyperglycemia like other antidiabetic agents of this large group affecting PPG such as incretin mimetics, DPP-4, etc. Both pramlintide and acarbose have find their specific in the treatment of postprandial blood glucose.

Key words:
amylin analogues – pramlintide – α-glucosidase inhibitors – acarbose – miglitol

Zdroje

1. Bronský J, Průša R. Biochemické markery v regulaci nutričního stavu. Klin Biochem Metab 2008; 16: 6–13.

2. Farooql IS, O’Rahilly S. Monogenic obesity in humans. Annu Rev Med 2005; 56: 443–458.

3. Bronský J, Nedvídková J, Zamrazilová H et al. Dynamic changes of orexin A, leptin and anthropometrical data in obese children during reduction of body weight. Physiol Res 2007; 56: 89–96.

4. Haluzík M, Svačina Š. Metabolický syndrom a nukleární receptory PPAR. Praha: Grada Publishing 2005.

5. Zhang JV, Ren PG, Avsian-Kretchmer O et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s effects on food intake. Science 2005; 310: 996–999.

6. Batterham RL, Le Roux CW, Cohen MA et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003; 88: 3989–3992.

7. Wimalawansa SJ. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: A peptide superfamily. Crit Rev Neurobiol 1997; 11: 167–239.

8. Macdonald IA. Amylin and the gastrointestinal tract. Diabet Med 1997; 14 (Suppl 2): S24–S28.

9. Juhl CB, Pørksen N, Sturis J et al. High-frequency oscillations in circulating amylin concentrations in healthy humans. Am J Physiol Endocrinol Metab 200; 278: E484–E490.

10. Nyholm B, Fineman MS, Koda JE et al. Plasma amylin immunoreactivity and insulin resistance in insulin resistant relatives of patients with non-insulin-dependent diabetes mellitus. Horm Metab Res 1998; 30: 206–212.

11. Cooper GJ, Willis AC, Clark A et al. Purification and characterization of a peptide from amyloid-rich pankreas of type 2 diabetic patients. Proc Natl Acad Sci USA 1987; 84: 8628–8632.

12. Kolterman OG. Amylin and glycaemic regulation: a possible role for the human amylin analogue pramlintide. Diabet Med 1997; 14 (Suppl 2): S35–S38.

13. Aronoff SL, Berkowitz K, Shreiner B et al. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectrum 2004; 17: 183–190.

14. Fineman MS, Koda JE, Shwen LZ et al. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 2002; 51: 636–641.

15. Roth JD, Roland BL, Cole RL et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA 2008; 105: 7257–7262.

16. Kruger DA, Gloster MA. Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data. Drugs 2004; 64: 1419–1432.

17. Guidobono F. Amylin and gastrointestinal activity. Gen Pharmac 1998; 31: 173–177.

18. Young A. Tissue expression and secretion of amylin. Adv Pharmacol 2005; 52: 19–45.

19. Bailey CJ, Krentz AJ. Oral Antidiabetic Agents. In: Holt RIG, Cockram CS, Flyvbjerg A et al (eds). Textbook of Diabetes. 4th ed. Singapore: Blackwell Publishing 2010; 452–477.

20. Perušičová J. Pramlintid – analog amylinu. In: Perušičová (ed.). Diabetes 2. typu – léčba. Praha: Geum 2010; 360–365.

21. Marrero DG, Crean J, Zhang B et al. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care 2007; 30: 210–216.

22. Alrefai HA, Latif KA, Hieronymus LB et al. Pramlintide: Clinical Strategie for Success. Diabetes Spectrum 2010; 23: 124–130.

23. Childs BP, Kesty NC, Klein E et al. Consediring Pramlintide Therapy for Postprandial Blood Glucose Control. Diabetes Spectrum 2007; 20: 108–114.

24. Chapman I, Parker B, Doran S et al. Effect pramlintide on satiety and food intake obese subjects and subjects with type 2 diabetes. Diabetologia 2005; 48: 838–848.

25. Smith SR, Aronne LJ, Burns CM et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008; 31: 1816–1823.

26. Rybka J, Gregorová A, Zmydlená A et al. Clinical Study of Acarbose. Drug Invest 1990; 2: 264–267.

27. Segal P, Schernthaner G, Rybka J et al. The efficacy and Safety of Miglitol Therapy Compared With Glibenclamide in Patients With NIDDM Inadequately Controlled by Diet Alone. Diabetes Care 1997; 20: 687–691.

28. Lhoret RR, Chiasson JL. α-Glucosidase Inhibitors in the Treatment pf Hyperglycemia. In: Lebovitz HE (ed.). Therapy for Diabetes Mellitus and Related Disorders. 4th ed. ADA 2004.

29. Gallwitz B. What should bet he second-line therapy after metformin in the overweight type 2 diabetic patient? In: Barnett AH (ed.). Diabetes Clinical Challenges. Oxford: Atlas Medical Publishing 2010; 73–89.

30. Chiasson JL, Josse RG, Hunt JA et al. The Efficacy of Acarbose in the Treatment of Patients with Non-Insulin-dependent Diabetes Mellitus. A Multicenter Controlled Clinical Trial. Ann Intern Med 1994; 121: 928–935.

31. Yamagishi S, Nakamura K, Takeuchi M. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome. Med Hypotheses 2005; 65: 152–154.

32. Yamagishi S, Matsui T, Ueda S et al. Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disordes. Curr Drug Metab 2009; 10: 159–163.

33. Fischer S, Hanefeld MN, Spengler M et al. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: Efficacy and safety of low and high doses. Acta Diabetol 1998; 35: 34–40.

34. Campbell LK. α-Glucosidase Inhibitors. In: White JR, Campbell RK (eds). ADA/PDR. Medications for the Treatment of Diabetes. ADA 2008, 115–123.

35. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005; 54: 1–7.

36. Leiter LA, Ceriello A, Davidson JA et al. International Prandial Glucose Regulation Study Group. Postprandial glucose regulation: new data and new implications. Clin Ther 2005; 27 (Suppl B): S42–S56.

37. Pelikánová T, Sechser T. Perorální antidiabetika a lékové interakce. In: Pelikánová T, Bartoš V et al (eds). Praktická diabetologie. 4. vyd. Praha: Maxdorf 2010, 194–219.

38. Rybka J. Měnící se strategie léčby diabetes mellitus 2. typu. Postgrad Med 2010; 12: 384–391.

39. Van de Laar FA, Lucassen PL, Akkermans RP et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 2: CD003639.

40. Hanefeld M, Fischer S, Schulze J et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991; 14: 732–737.

41. Clement S. What are the best options for controlling prandial glycemia? Curr Diab Rep 2009; 9: 355–359.

42. Chiasson JL. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract 2006; 12 (Suppl 1): 25–30.

43. Bao YQ, Zhou J, Zhou M et al. Glipizide controlled-release tablets with or without acarbose improves glycemic variability in newly diagnosed type 2 diabetes. Clin Exp Pharmacol Physiol 2010; 37: 564–568.

44. Derosa G, Salvadeo SA, D’Angelo A et al. Metabolic effect of repaglinide or acarbose when addend to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Curr Med Res Opin 2009; 25: 607–615.

45. Duran C, Tuncel E, Ersoy C et al. The investigation of the efficacy of insulin glargine on glycemic control when combined with ether repaglinide or acarbose in obese Type 2 diabetic patients. J Endocrinol Invest 2009; 32: 69–73.

46. Hanefeld M, Cagatay M, Petrowitsch T et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10–16.

47. Hanefeld M, Schaper F, Koehler C. Effect of acarbose on vascular disease in patients with abnormal glucose tolerance. Cardiovasc Drug Ther 2008; 22: 225–231.

48. Rosak C, Mertes G. Effects of acarbose on proinsulin and insulin secretion and their potential significance for the intermediary, metabolism and cardiovascular system. Curr Diabetes Rev 2009; 5: 157–164.

49. Chiasson JL, Josse RG, Gomis R et al. STOP-NIDDM Trial Research Group. Acarbose Treatment and the Risk of Cardiovascular Diasease and Hypertension in Patients With Impaired Glucose Tolerance. The STOP-NIDDM Trial. JAMA 2003; 290: 486–494.

50. Minatoguchi S, Zhang Z, Bao N et al. Acarbose reduces myocardial infarct size by preventing postprandial hyperglycemia and hydroxyl radical production and opening mitochondrial KATP channels in rabbits. J Cardiovasc Pharmacol 2009; 54: 25–30.

51. Phillips P, Karrasch J, Scott R et al. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 2003; 26: 269–273.

52. Holst JJ, Madsbad S, Schmitz O. Non-Insulin Parenteral Therapies. In: Holt RIG, Cockram CS, Flyvbjerg A et al (eds). Textbook of Diabetes. 4th ed. Blackwell Publishing 2010; 478–493.

53. Uličiansky V. Liečba diabetes mellitus 2. typu. In: Mokáň M, Martinka E, Galajda P et al (eds). Diabetes mellitus a vybrané metabolické ochorenia. Martin: Vydavatelstvo P + M 2008; 276–322.

54. Chiasson JL. α-Glucosidase Inhibitors. In: Fonseca VA (ed.). Clinical Diabetes – Translating Research into Practice. Philadelphia: Saunders Elsevier 2006; 322–331.